Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | Any |
| Updated: | 5/16/2018 |
| Start Date: | August 2010 |
| End Date: | August 2025 |
| Contact: | L. Allyson Checkley, PhD |
| Email: | laura.checkley@coramhc.com |
| Phone: | 303.672.8888 |
The IDEaL registry is a cooperative, observational registry focused on immunoglobulin use in
the U.S. The registry is a deliberate and purposeful assembly of clinical and humanistic
knowledge that is intended to act as a longitudinal database, tracking outcomes of routine
clinical practice.
The central goal of the registry is to provide a mechanism that allows for a better
understanding of how immunoglobulin therapy is being used in a real-world clinical setting.
The data gathered will help the industry gain a better understanding surrounding the
therapeutic value of immunoglobulin therapy and subsequently improve practices, reduce
medical costs, and ultimately improve the clinical outcomes for the patients receiving
immunoglobulin therapy
the U.S. The registry is a deliberate and purposeful assembly of clinical and humanistic
knowledge that is intended to act as a longitudinal database, tracking outcomes of routine
clinical practice.
The central goal of the registry is to provide a mechanism that allows for a better
understanding of how immunoglobulin therapy is being used in a real-world clinical setting.
The data gathered will help the industry gain a better understanding surrounding the
therapeutic value of immunoglobulin therapy and subsequently improve practices, reduce
medical costs, and ultimately improve the clinical outcomes for the patients receiving
immunoglobulin therapy
The registry's goal is to significantly contribute to the medical understanding of Ig therapy
and to improve the quality of care for patients receiving Ig therapy in the United States
through active publication of registry findings and disease management approaches.
The IDEaL program represents a unique and powerful method for the collection of:
Patient Level / Humanistic Data / Quality of Life Physician Level / Practice Patterns
Clinical Data / Therapeutic Outcomes Reimbursement / Impact on Treatment / Policy Decisions
Whereby:
Accelerating innovation Producing faster knowledge gains Improving awareness of patient
outcomes and disease burden Providing a clearer understanding of therapy impact on patients'
quality of life.
The objectives of the Registry are:
to enhance the understanding of the variability, progression, and natural history of disease
requiring Ig therapy with the ultimate goal of better guiding and assessing therapeutic
intervention; to provide the Ig medical community with recommendations for monitoring
patients and to provide reports on patient outcomes to help optimize patient care; and to
serve as an active knowledge base that can provide population-management information, which
can be used to generate patient-management and practice-management tools; and
and to improve the quality of care for patients receiving Ig therapy in the United States
through active publication of registry findings and disease management approaches.
The IDEaL program represents a unique and powerful method for the collection of:
Patient Level / Humanistic Data / Quality of Life Physician Level / Practice Patterns
Clinical Data / Therapeutic Outcomes Reimbursement / Impact on Treatment / Policy Decisions
Whereby:
Accelerating innovation Producing faster knowledge gains Improving awareness of patient
outcomes and disease burden Providing a clearer understanding of therapy impact on patients'
quality of life.
The objectives of the Registry are:
to enhance the understanding of the variability, progression, and natural history of disease
requiring Ig therapy with the ultimate goal of better guiding and assessing therapeutic
intervention; to provide the Ig medical community with recommendations for monitoring
patients and to provide reports on patient outcomes to help optimize patient care; and to
serve as an active knowledge base that can provide population-management information, which
can be used to generate patient-management and practice-management tools; and
Inclusion Criteria:
- Signed informed consent
- Any age, disease, or gender requiring Ig therapy
- Agree to the use of Coram's infusion services after entry into IDEaL Registry
We found this trial at
1
site
Denver, Colorado 80202
Principal Investigator: Luqman Seidu, MD
Phone: 303-672-8888
Click here to add this to my saved trials
